Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia

British Journal of Haematology

Volumn 164, Issue 2, 2014, Pages 245-250

  Medeiros, Bruno C ^a   Othus, Megan ^b,c   Estey, Elihu H ^b,d   Fang, Min ^b,d   Appelbaum, Frederick R ^b,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c SWOG STATISTICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute myeloid leukaemia; Karyotype; Overall survival; Unfavourable karyotype; Unsuccessful metaphase analysis

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ACUTE MYELOID LEUKAEMIA; KARYOTYPE; OVERALL SURVIVAL; UNFAVOURABLE KARYOTYPE; UNSUCCESSFUL METAPHASE ANALYSIS;

ADULT; AGED; CHROMOSOME BANDING; CYTOGENETIC ANALYSIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84891625028     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12625     Document Type: Article

References (14)

1. Byrd, J.C., Mrózek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Patil, S.R., Rao, K.W., Watson, M.S., Koduru, P.R., Moore, J.O., Stone, R.M., Mayer, R.J., Feldman, E.J., Davey, F.R., Schiffer, C.A., Larson, R.A., Bloomfield, C.D. & Cancer and Leukemia Group B (CALGB 8461). (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100, 4325-4336.
2. Cervera, J., Solé, F. & Haase, D. (2009) Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS). Leukemia Research, 33(S1), S75-S76.
3. Cox, D.R. (1972) Regression models and life-tables (with discussion). Journal of the Royal Statistical Society. Series B, Statistical Methodology, 34, 187-220.
4. Dougherty, M.J., Wilmoth, D.M., Tooke, L.S., Shaikh, T.H., Gai, X., Hakonarson, H. & Biegel, J.A. (2011) Implementation of high resolution single nucleotide polymorphism array analysis as a clinical test for patients with hematologic malignancies. Cancer Genetics, 204, 26-38.
5. Fischer, K., Scholl, C., Sàlat, J., Fröhling, S., Schlenk, R., Bentz, M., Stilgenbauer, S., Lichter, P. & Döhner, H. (1996) Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia. Blood, 88, 3962-3971.
6. Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J., Burnett, A.K. & National Cancer Research Institute Adult Leukaemia Working Group. (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354-65.
7. International System for Human Cytogenetic Nomenclature. (2005) An International System for Human Cytogenetic Nomenclature. S. Karger, Basel, Switzerland.
8. List, A.F., Kopecky, K.J., Willman, C.L., Head, D.R., Persons, D.L., Slovak, M.L., Dorr, R., Karanes, C., Hynes, H.E., Doroshow, J.H., Shurafa, M. & Appelbaum, F.R. (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood, 98, 3212-3220.
9. Löwenberg, B., Ossenkoppele, G.J., van Putten, W., Schouten, H.C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., Biemond, B.J., Vellenga, E., van Marwijk Kooy, M., Verdonck, L.F., Beck, J., Döhner, H., Gratwohl, A., Pabst, T., Verhoef, G.; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG) & Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. New England Journal of Medicine, 361, 1235-1248.
10. Löwenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H.C., Graux, C., Ferrant, A., Sonneveld, P., Biemond, B.J., Gratwohl, A., de Greef, G.E., Verdonck, L.F., Schaafsma, M.R., Gregor, M., Theobald, M., Schanz, U., Maertens, J., Ossenkoppele, G.J.; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) & Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. (2011) Cytarabine dose for acute myeloid leukemia. New England Journal of Medicine, 364, 1027-1036.
11. Medeiros, B.C., Othus, M., Fang, M., Roulston, D. & Appelbaum, F.R. (2010) Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood, 116, 2224-2228.
12. Schiffer, C.A., Lee, E.J., Tomiyasu, T., Wiernik, P.H. & Testa, J.R. (1989) Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood, 73, 263-270.
13. Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, K.S., Mohamed, A., Paietta, E., Willman, C.L., Head, D.R., Rowe, J.M., Forman, S.J. & Appelbaum, F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood, 96, 4075-4083.
14. Tiu, R.V., Gondek, L.P., O'Keefe, C.L., Huh, J., Sekeres, M.A., Elson, P., McDevitt, M.A., Wang, X.F., Levis, M.J., Karp, J.E., Advani, A.S. & Maciejewski, J.P. (2009) New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. Journal of Clinical Oncology, 27, 5219-5226.